J. P. Ashby

2.6k total citations
89 papers, 2.2k citations indexed

About

J. P. Ashby is a scholar working on Pharmacology, Epidemiology and Molecular Medicine. According to data from OpenAlex, J. P. Ashby has authored 89 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Pharmacology, 23 papers in Epidemiology and 22 papers in Molecular Medicine. Recurrent topics in J. P. Ashby's work include Antibiotics Pharmacokinetics and Efficacy (30 papers), Antibiotic Resistance in Bacteria (22 papers) and Pneumonia and Respiratory Infections (19 papers). J. P. Ashby is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (30 papers), Antibiotic Resistance in Bacteria (22 papers) and Pneumonia and Respiratory Infections (19 papers). J. P. Ashby collaborates with scholars based in United Kingdom, United States and France. J. P. Ashby's co-authors include Robert A. Wise, J. M. Andrews, J. M. Andrews, D. Honeybourne, David Baldwin, F. J. Boswell, Richard Matthews, R. N. Speake, Brian M. Frier and D. J. Griggs and has published in prestigious journals such as American Journal of Clinical Nutrition, The Journal of Clinical Endocrinology & Metabolism and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

J. P. Ashby

88 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. P. Ashby United Kingdom 26 895 713 588 423 384 89 2.2k
F. Sörgel Germany 29 1.3k 1.4× 646 0.9× 571 1.0× 303 0.7× 285 0.7× 99 2.6k
P Periti Italy 21 450 0.5× 505 0.7× 175 0.3× 283 0.7× 216 0.6× 107 1.9k
Riccardo Utili Italy 34 574 0.6× 2.7k 3.8× 750 1.3× 420 1.0× 913 2.4× 145 4.8k
Hans Georg Eichler Austria 26 700 0.8× 321 0.5× 168 0.3× 200 0.5× 117 0.3× 52 1.9k
I. Nilsson-Ehle Sweden 24 865 1.0× 357 0.5× 318 0.5× 195 0.5× 216 0.6× 58 1.8k
Veronique Stove Belgium 25 985 1.1× 544 0.8× 353 0.6× 360 0.9× 158 0.4× 81 2.0k
Sébastien Tanaka France 27 436 0.5× 677 0.9× 616 1.0× 286 0.7× 487 1.3× 69 2.1k
Mao Hagihara Japan 28 430 0.5× 675 0.9× 336 0.6× 534 1.3× 712 1.9× 168 2.3k
J. D. Baumgartner Switzerland 21 261 0.3× 905 1.3× 158 0.3× 424 1.0× 145 0.4× 35 2.6k
Lennart Nilsson Sweden 26 357 0.4× 333 0.5× 385 0.7× 238 0.6× 287 0.7× 62 1.7k

Countries citing papers authored by J. P. Ashby

Since Specialization
Citations

This map shows the geographic impact of J. P. Ashby's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. P. Ashby with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. P. Ashby more than expected).

Fields of papers citing papers by J. P. Ashby

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. P. Ashby. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. P. Ashby. The network helps show where J. P. Ashby may publish in the future.

Co-authorship network of co-authors of J. P. Ashby

This figure shows the co-authorship network connecting the top 25 collaborators of J. P. Ashby. A scholar is included among the top collaborators of J. P. Ashby based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. P. Ashby. J. P. Ashby is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ashby, J. P., et al.. (2025). Ofatumumab Associated Legionella Pneumonia in a Young Multiple Sclerosis Patient. American Journal of Respiratory and Critical Care Medicine. 211(Supplement_1). A6747–A6747.
2.
Zammitt, Nicola N., J. Geddes, Roderick E. Warren, et al.. (2007). Serum angiotensin‐converting enzyme and frequency of severe hypoglycaemia in Type 1 diabetes: does a relationship exist?. Diabetic Medicine. 24(12). 1449–1454. 29 indexed citations
3.
Andrews, J. M., et al.. (2000). A comparison of antimicrobial resistance rates in Gram-positive pathogens isolated in the UK from October 1996 to January 1997 and October 1997 to January 1998. Journal of Antimicrobial Chemotherapy. 45(3). 285–293. 31 indexed citations
4.
Wise, Robert A., J. M. Andrews, J. P. Ashby, & James D. Marshall. (1999). A study to determine the pharmacokinetics and inflammatory fluid penetration of gatifloxacin following a single oral dose. Journal of Antimicrobial Chemotherapy. 44(5). 701–704. 28 indexed citations
5.
Wise, Robert A., J. M. Andrews, F. J. Boswell, & J. P. Ashby. (1998). The in-vitro activity of linezolid (U-100766) and tentative breakpoints. Journal of Antimicrobial Chemotherapy. 42(6). 721–728. 135 indexed citations
6.
Ashby, J. P., David Newman, & Sean Gow. (1997). Clinical Application of Intact Parathyroid Hormone Assays. Annals of Clinical Biochemistry International Journal of Laboratory Medicine. 34(6). 588–598. 9 indexed citations
7.
Wallace, Euan M., I. A. Swanston, Alan S. McNeilly, et al.. (1996). Second trimester screening for Down's syndrome using maternal serum dimeric inhibin A. Clinical Endocrinology. 44(1). 17–21. 65 indexed citations
8.
Reeve, J., Jeremy N. Bradbeer, M. Arlot, et al.. (1991). hPTH 1–34 treatment of osteoporosis with added hormone replacement therapy: Biochemical, kinetic and histological responses. Osteoporosis International. 1(3). 162–170. 101 indexed citations
9.
Baldwin, David, et al.. (1990). Concentrations of temafloxacin in serum and bronchial mucosa. European Journal of Clinical Microbiology & Infectious Diseases. 9(6). 432–434. 11 indexed citations
10.
Wise, Robert A., et al.. (1990). Ceftibuten—in-vitro activity against respiratory pathogens, β-lactamase stability and mechanism of action. Journal of Antimicrobial Chemotherapy. 26(2). 209–213. 17 indexed citations
11.
Cooper, Melisa, J. M. Andrews, J. P. Ashby, Richard Matthews, & R. Wise. (1990). In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent. Journal of Antimicrobial Chemotherapy. 26(5). 667–676. 53 indexed citations
12.
Cooper, Melisa, Ye Jin, J. P. Ashby, J. M. Andrews, & Robert I. Wise. (1990). In-vitro comparison of the postantibiotic effect of vancomycin and teicoplanin. Journal of Antimicrobial Chemotherapy. 26(2). 203–207. 16 indexed citations
13.
Ashby, J. P., et al.. (1989). Intraperitoneal penetration of cefpirome. European Journal of Clinical Microbiology & Infectious Diseases. 8(6). 556–558. 4 indexed citations
14.
Nye, K., Yi Shi, J. M. Andrews, J. P. Ashby, & Robert A. Wise. (1989). The in-vitro activity, pharmacokinetics and tissue penetration of temafloxacin. Journal of Antimicrobial Chemotherapy. 24(3). 415–424. 42 indexed citations
15.
Gupta, Vatsala, et al.. (1989). Effect of aspartame on plasma amino acid profiles of diabetic patients with chronic renal failure. American Journal of Clinical Nutrition. 49(6). 1302–1306. 5 indexed citations
16.
Wise, Robert A., J. P. Ashby, & J. M. Andrews. (1989). The antibacterial activity of meropenem in combination with gentamicin or vancomycin. Journal of Antimicrobial Chemotherapy. 24(suppl A). 233–238. 16 indexed citations
17.
Wise, R., et al.. (1988). The penetration of fleroxacin into bronchial mucosa. Journal of Antimicrobial Chemotherapy. 22(2). 203–206. 21 indexed citations
18.
Andrews, J. M., et al.. (1988). Pharmacokinetics and tissue penetration of cefpirome, a new cephalosporin. Journal of Antimicrobial Chemotherapy. 22(6). 911–916. 28 indexed citations
19.
Ashby, J. P. & B M Frier. (1988). Is Serum Fructosamine a Clinically Useful Test?. Diabetic Medicine. 5(2). 118–121. 16 indexed citations
20.
Wise, R., et al.. (1988). The pharmacokinetics and tissue penetration of intravenously administered CGP 31608. Journal of Antimicrobial Chemotherapy. 21(1). 85–91. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by F. Sörgel Breakdown of academic impact, for papers by P Periti Breakdown of academic impact, for papers by Riccardo Utili Breakdown of academic impact, for papers by Hans Georg Eichler Breakdown of academic impact, for papers by I. Nilsson-Ehle Breakdown of academic impact, for papers by Veronique Stove Breakdown of academic impact, for papers by Sébastien Tanaka Breakdown of academic impact, for papers by Mao Hagihara Breakdown of academic impact, for papers by J. D. Baumgartner Breakdown of academic impact, for papers by Lennart Nilsson
Rankless by CCL
2026